Kamada Ltd - KMDA STOCK NEWS

Kamada (NASDAQ: KMDA) announced it will release its Q3 and nine-months financial results for the period ended September 30, 2024, before U.S. markets open on November 13, 2024. The company will host an investment community conference call at 8:30am Eastern Time on the same day. Shareholders can participate by dialing specific numbers for U.S., Israel, and International access. The call will also be available via webcast.

Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, announced its participation in the Stifel 2024 Healthcare Conference in New York. CEO Amir London will deliver a corporate overview on November 18, 2024, at 10:55 a.m. ET. The event will be held from November 18-19, 2024. Investors can arrange one-on-one meetings through Stifel representatives, and a live webcast will be available on Kamada's website with a 30-day replay option.

Kamada (NASDAQ: KMDA; TASE: KMDA.TA) has expanded its plasma collection operations by opening a new center in Houston, TX. The 12,000 square foot facility, operated by Kamada Plasma, is designed to support over 50 donor beds with an estimated annual collection capacity of 50,000 liters. It will collect both normal source plasma and specialty plasma, such as Anti-Rabies and Anti-D, and is expected to be one of the largest specialty plasma collection sites in the U.S.

The company plans to submit regulatory applications to the FDA and EMA in the first half of 2025 for approval of the Houston site. Kamada is also constructing a third plasma collection center in San Antonio, TX, set to open in the first half of 2025. Each center is projected to contribute annual revenues of $8 million to $10 million in sales of normal source plasma at full capacity.

Kamada reported strong financial results for Q2 and H1 2024. Revenues for Q2 2024 were $42.5 million, a 13% increase YoY, and $80.2 million for H1 2024, up 18% YoY. Q2 2024 adjusted EBITDA was $9.1 million, a 51% increase YoY, and $16.6 million for H1 2024, up 68% YoY. Net income for Q2 2024 was $4.4 million ($0.08 per share), and $6.8 million ($0.12 per share) for H1 2024. Kamada reiterated its full-year revenue guidance of $158-$162 million and adjusted EBITDA of $28-$32 million. Increased sales of KEDRAB and CYTOGAM in the US market were primary revenue drivers. Operating expenses rose due to higher S&M and R&D costs associated with marketing and the advanced Inhaled AAT clinical trial. Kamada generated $15.0 million of cash from operating activities in H1 2024 and held $56.5 million in cash and equivalents as of June 30, 2024. The company continues to explore new business opportunities and expects double-digit growth beyond 2024.

Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has announced its upcoming financial results release. The company will disclose its second quarter and first half 2024 financial results on August 14, 2024, before U.S. financial markets open.

Following the release, Kamada's management will host an investment community conference call at 8:30am Eastern Time on the same day. Shareholders and interested parties can participate via phone or webcast. The call will be archived on the company's website for 90 days.

Kamada reported strong first quarter 2024 financial results with a 23% increase in revenues and a 96% rise in profitability. The company's top-line growth was driven by U.S. sales of KEDRAB® and CYTOGAM®. Kamada increased its full-year revenue guidance to $158-162 million and adjusted EBITDA to $28-32 million. The company remains optimistic about its growth prospects beyond 2024.

Kamada will announce its first quarter 2024 financial results on May 8, 2024, before the U.S. financial markets open. The company, known for its rare condition treatments, will host an investment community conference call to discuss the results.

Kamada Ltd. reports successful financial results for 2023, with total revenues of $142.5 million and adjusted EBITDA of $24.1 million, representing margins of 17%. The company expects further growth in 2024, with revenue guidance of $156-160 million and adjusted EBITDA guidance of $27-30 million. Key drivers include increased sales of KEDRAB anti-rabies immunoglobulin and promotion of CYTOGAM. The extended distribution agreement with Kedrion guarantees significant revenues, with $180 million expected in the first four years. Kamada's U.S. team is making progress in promoting their portfolio, including CYTOGAM and VARIZIG. The company continues to expand internationally, focusing on territories like Canada, Asia, Latin America, and the Middle East.

Kamada Ltd. (KMDA) reports record annual revenues of $142.5 million for fiscal year 2023, a 10% increase from 2022. Adjusted EBITDA was $24.1 million, up 35% year-over-year. The company expects double-digit growth in fiscal year 2024 with anticipated revenues of $156-160 million and adjusted EBITDA of $27-30 million. Kamada also announced an extended U.S. distribution agreement with Kedrion for KEDRAB® with $180 million in revenues over four years. Positive FDA feedback on Phase 3 AAT clinical trial was received. Financially, total revenues grew, but net income for 2023 was $8.3 million compared to a loss in 2022. Cash provided by operating activities decreased to $4.3 million from $28.6 million in the prior year.